David Hysong | Founder & CEO, SHEPHERD Therapeutics
I initially hired G2G to pursue federal grants for rare cancer research. In the past two years, they have planned, engineered, and executed an entire, comprehensive initiative to fundamentally change the way our country spends federal dollars on cancer research and development. Of their own initiative, G2G has drafted comprehensive policy proposals, submitted hundreds of appropriations requests, held over 1,000 meetings with various Congressional offices and agencies, and set up Congressional briefings with partners such as the NCI, NCATS, Biden Cancer Initiative, the NIH and many others. Liz and her team have blown away every expectation – I could not recommend them enough. They have my unending gratitude, respect, and will continue to be partners with SHEPHERD for a very long time.